当前位置:首页 - 行情中心 - 翔宇医疗(688626) - 财务分析 - 利润表

翔宇医疗

(688626)

  

流通市值:98.11亿  总市值:98.11亿
流通股本:1.60亿   总股本:1.60亿

利润表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、营业总收入193,080,689.91767,747,443.44537,029,843.94359,046,551.97
  营业收入193,080,689.91767,747,443.44537,029,843.94359,046,551.97
二、营业总成本168,290,426.45726,616,071.69520,270,525.26344,135,390.19
  营业成本61,397,644.19256,205,489.55176,200,348.34115,231,844.65
  税金及附加3,070,270.8213,233,453.89,483,496.126,121,955.86
  销售费用51,418,819.88232,872,273.82174,195,801.75116,147,261.14
  管理费用16,128,262.2565,110,864.1244,840,918.2828,641,110.36
  研发费用37,947,523.89175,061,698.12125,479,123.8784,231,554.82
  财务费用-1,672,094.58-15,867,707.72-9,929,163.1-6,238,336.64
  其中:利息费用2,208,760.735,695,731.795,490,412.233,930,734.74
  其中:利息收入4,564,336.9223,015,837.8516,765,084.3811,351,874.55
三、其他经营收益
  加:公允价值变动收益-501,026--
  加:投资收益-1,327,129.015,939,079.556,134,907.396,082,117.6
  资产处置收益-1,026.6526,252.9326,252.9321,374.06
  资产减值损失(新)-1,361,027.35-8,064,545.2-4,269,406.9-2,353,330.71
  信用减值损失(新)-928,364.17-3,436,954.48-1,769,790.2-279,901.84
  其他收益5,537,729.1540,612,286.128,696,677.5321,971,622
四、营业利润26,710,445.4376,708,516.6545,577,959.4340,353,042.89
  加:营业外收入22,195.7597,618.8172,884.8447,736.77
  减:营业外支出66,453.82,374,558.531,345,418.41,331,806.99
五、利润总额26,666,187.3874,431,576.9344,305,425.8739,068,972.67
  减:所得税费用1,766,226.46-1,555,369.112,397,983.125,586,779.51
六、净利润24,899,960.9275,986,946.0441,907,442.7533,482,193.16
(一)按经营持续性分类
  持续经营净利润24,899,960.9275,986,946.0441,907,442.7533,482,193.16
(二)按所有权归属分类
  归属于母公司股东的净利润25,322,010.278,156,441.9743,981,544.7235,394,674.93
  少数股东损益-422,049.28-2,169,495.93-2,074,101.97-1,912,481.77
  扣除非经常损益后的净利润23,293,091.6858,273,346.5929,939,629.0523,033,650.88
七、每股收益
  (一)基本每股收益0.160.510.290.23
  (二)稀释每股收益0.210.60.290.23
九、综合收益总额24,899,960.9275,986,946.0441,907,442.7533,482,193.16
  归属于母公司股东的综合收益总额25,322,010.278,156,441.9743,981,544.7235,394,674.93
  归属于少数股东的综合收益总额-422,049.28-2,169,495.93-2,074,101.97-1,912,481.77
公告日期2026-04-242026-04-242025-10-312025-08-29
审计意见(境内)标准无保留意见
TOP↑